Amarin | AMRN - Cost Of Sales

Stock Price
14.30
Daily Change
0.34 2.44%
Monthly
2.51%
Yearly
32.90%
Q2 Forecast
13.88

Amarin reported $26.05M in Cost of Sales for its fiscal quarter ending in December of 2025.





Cost Of Sales Change Date
AbbVie USD 4.22B 329M Mar/2026
Alnylam Pharmaceuticals USD 267.72M 67.57M Dec/2025
Amarin USD 26.05M 1.41M Dec/2025
AstraZeneca USD -204M 3.48B Mar/2026
BioCryst Pharmaceuticals USD 9.52M 7.34M Dec/2025
Esperion Therapeutics USD 27.85M 13.43M Dec/2025
GlaxoSmithKline GBP 1.88B 736M Mar/2026
Halozyme Therapeutics USD 102.15M 29.14M Dec/2025
Heron Therapeutics USD 11.12M 795K Dec/2025
Ionis Pharmaceuticals USD 3M 5M Mar/2026
Nektar Therapeutics USD 4.43M 5.3M Sep/2024
Neurocrine Biosciences USD 17.6M 246.4M Dec/2025
Novartis USD 3.54B 3M Dec/2025